Biotechnology Approaches for the Treatment of Dyslipidemia.

Cardiovascular Drugs and Therapy
Cinzia Parolini

Abstract

Despite advances in the development of lipid-lowering therapies, clinical trials have shown that a significant residual risk of cardiovascular disease persists. Specifically, new drugs are needed for non-responding or statin-intolerant subjects or patients considered at very high risk for cardiovascular events even though are already on treatment with the best standard of care. Besides, genetic and epidemiological studies and Mendelian randomization analyses have strengthened the linear correlation between the concentration of low-density lipoprotein cholesterol (LDL-C) and the incidence of cardiovascular events and highlighted various novel therapeutic targets. This review describes the novel strategies to reduce the levels of LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a), focusing on those developed using biotechnology-based strategies.

References

Apr 25, 1988·Nucleic Acids Research·C A SteinJ S Cohen
Jan 1, 1994·Journal of Cardiovascular Pharmacology·M R SomaA L Catapano
Jan 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nabil G SeidahMichel Chretien
Oct 4, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Daniel J Rader
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Dec 16, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Tommaso FasanoPatrizia Tarugi
Jan 15, 2008·Nature Genetics·Cristen J WillerGonçalo R Abecasis
Jun 4, 2008·Current Opinion in Cardiology·Giulia ChiesaCesare R Sirtori
Dec 17, 2008·The Journal of Clinical Investigation·Stefano RomeoJonathan C Cohen
Jun 3, 2009·Current Vascular Pharmacology·Cinzia ParoliniGiulia Chiesa
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·C Frank Bennett, Eric E Swayze
Nov 9, 2011·Circulation. Cardiovascular Genetics·Livia PisciottaStefano Bertolini
Apr 19, 2012·Current Opinion in Lipidology·Zemin Yao, Yuwei Wang
Jul 20, 2012·Journal of Lipid Research·Gilles LambertG Kees Hovingh
Nov 2, 2012·The New England Journal of Medicine·Eli M RothEvan A Stein
Apr 9, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Eveline P van PoelgeestJacobus Burggraaf
May 11, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Marius R RobciucMatti Jauhiainen
May 25, 2013·Circulation Research·Murray W Huff, Robert A Hegele
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Andrew J MurphyGeorge D Yancopoulos

❮ Previous
Next ❯

Citations

Jan 12, 2021·Frontiers in Pharmacology·Cinzia Parolini, Amedeo Amedei
May 1, 2021·Current Opinion in Cardiology·Camelia C DiaconuManfredi Rizzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Related Papers

European Heart Journal. Cardiovascular Pharmacotherapy
Ian GrahamEuropean Society of Cardiology Cardiovascular Roundtable
Postgraduate Medicine
Christie M Ballantyne
© 2022 Meta ULC. All rights reserved